Want to see MAZE full AI Analyst Report?
Top Page
Maze Therapeutics, Inc.
(NASDAQ:MAZE)
Select Model
Select Model
Rating:46Neutral
Price Target:
$29.00
▲(3.24% Upside)
Action:Reiterated
Date:06/11/26
The score is held down primarily by weak financial performance (large losses and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events modestly offset this by improving funding/runway via the equity raise, while valuation is constrained by the negative P/E due to losses.
Positive Factors
Balance Sheet Strength
Low leverage and a sizable equity cushion provide durable financial flexibility for a clinical‑stage biotech. This reduces near‑term refinancing risk, supports multi‑year R&D spend, and increases the company's ability to weather trial delays without immediate disruptive financing.
Negative Factors
Sustained Cash Burn
Large and persistent negative operating and free cash flows signal ongoing funding needs. Until revenues or positive operating leverage emerge, the company will rely on capital markets, raising dilution risk and creating vulnerability if market access tightens or financing terms worsen.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Low leverage and a sizable equity cushion provide durable financial flexibility for a clinical‑stage biotech. This reduces near‑term refinancing risk, supports multi‑year R&D spend, and increases the company's ability to weather trial delays without immediate disruptive financing.
Read all positive factors
Maze Therapeutics, Inc. (MAZE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.65B
Dividend YieldN/A
Average Volume (3M)526.33K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees141
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.75
Shares Outstanding55,345,260
10 Day Avg. Volume659,433
30 Day Avg. Volume526,332
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue61.86
Enterprise Value/Gross Profit67.21
Enterprise Value/Ebitda-10.35
Forecast
1Y Price Target
$70.00Price Target Upside149.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$22.22M
Maze Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhi...
How the Company Makes Money
null...
Maze Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.00M | 0.00 | 167.50M | 0.00 | 0.00 |
| Gross Profit | 18.41M | -2.40M | 167.50M | 0.00 | 0.00 |
| EBITDA | -119.51M | -128.72M | 56.70M | -96.33M | -111.12M |
| Net Income | -122.54M | -131.12M | 52.23M | -100.42M | -114.94M |
Balance Sheet | |||||
| Total Assets | 419.71M | 397.13M | 240.54M | 71.50M | 149.96M |
| Cash, Cash Equivalents and Short-Term Investments | 352.38M | 341.92M | 196.81M | 29.16M | 99.92M |
| Total Debt | 61.22M | 23.31M | 26.63M | 49.62M | 32.05M |
| Total Liabilities | 78.01M | 42.16M | 43.64M | 61.45M | 48.51M |
| Stockholders Equity | 341.70M | 354.97M | 196.90M | 10.05M | 101.44M |
Cash Flow | |||||
| Free Cash Flow | -122.13M | -112.73M | 74.81M | -87.27M | -101.17M |
| Operating Cash Flow | -121.54M | -111.94M | 75.95M | -86.83M | -99.20M |
| Investing Cash Flow | -164.39M | -170.96M | -1.15M | -441.00K | -3.17M |
| Financing Cash Flow | 190.32M | 275.34M | 92.85M | 16.39M | 1.73M |
Maze Therapeutics, Inc. Risk Analysis
Maze Therapeutics, Inc. disclosed 83 risk factors in its most recent earnings report. Maze Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Maze Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $615.85M | 3.26 | 50.38% | ― | 384.60% | 883.51% | |
60 Neutral | $1.96B | -79.45 | 442.91% | ― | 107.73% | 82.33% | |
57 Neutral | $1.94B | ― | -44.10% | ― | 1205.52% | 81.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $821.15M | -12.32 | -28.90% | ― | 68.64% | 50.57% | |
46 Neutral | $1.65B | -10.76 | -36.63% | ― | ― | ― |
* Healthcare Sector Average
MAZE
Maze Therapeutics, Inc.
29.84
18.18
155.92%
CRMD
Cormedix
7.85
-3.94
-33.42%
GERN
Geron
1.28
-0.10
-7.25%
ANAB
AnaptysBio
67.50
52.40
347.11%
NUVB
Nuvation Bio
5.68
3.74
192.78%
Maze Therapeutics, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
Positive
Jun 10, 2026
On June 8, 2026, Maze Therapeutics, Inc. held its 2026 annual meeting of stockholders with 44,660,029 shares of common stock represented, or about 89.75% of shares entitled to vote, establishing a quorum for business. Stockholders voted on the ele...
Executive/Board Changes
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change
Neutral
May 22, 2026
On May 18, 2026, Maze Therapeutics, Inc. announced that Senior Vice President of Finance Amy Bachrodt had submitted her resignation, effective June 1, 2026, noting that her departure did not stem from any disagreement over the company’s oper...
Business Operations and StrategyPrivate Placements and Financing
Maze Therapeutics prices $150 million equity offering
Positive
Apr 22, 2026
On April 21, 2026, Maze Therapeutics, Inc. priced an underwritten registered offering of 5,540,000 shares of common stock at $23.50 per share and pre-funded warrants for 850,000 shares at $23.499, for expected gross proceeds of $150 million and es...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.